{"id":"W4319826851","doi":"10.1182/bloodadvances.2022008866","title":"Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb; Amgen","keywords":"Daratumumab; Medicine; Carfilzomib; Pomalidomide; Internal medicine; Multiple myeloma; Confidence interval; Dexamethasone; Oncology; Lenalidomide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002108506,0.0001852624,0.0004881074,0.0002833979,0.00008008533,0.00001552534,0.00005435387,0.00004180362,0.000006129299],"category_scores_gemma":[0.0002766274,0.0001311537,0.0000191724,0.0005466904,0.0001492067,0.0001386775,0.00007147765,0.0001434342,0.000002611403],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001326114,"about_ca_system_score_gemma":0.00004413587,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003004833,"about_ca_topic_score_gemma":0.0009690843,"domain_scores_codex":[0.9985923,0.00008417332,0.0002555345,0.0003950317,0.0003308966,0.0003420431],"domain_scores_gemma":[0.9992011,0.0002184096,0.00008401401,0.0002425263,0.00007087497,0.0001830377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004021394,0.00283514,0.9698358,0.0001754354,0.0002286511,0.0007459644,0.001155978,0.000006427289,0.004337132,0.0000104404,0.00000483722,0.01664282],"study_design_scores_gemma":[0.1381268,0.01037032,0.8345631,0.000227014,0.0002115912,0.0001220705,0.005703427,0.0005660468,0.0097192,0.00003362903,0.0001636847,0.0001930965],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962156,0.002132885,0.000003016712,0.00005506599,0.00001592122,0.001233173,0.00001962202,0.00005428263,0.0002704177],"genre_scores_gemma":[0.9978276,0.0003602294,0.001274254,0.000009339629,0.00002097537,0.0001327384,0.00001846201,0.00002456395,0.000331763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1352727,"threshold_uncertainty_score":0.5348294,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02775344379533928,"score_gpt":0.3433425223205218,"score_spread":0.3155890785251825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}